Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find
tumor cells and help kill them or carry tumor-killing substances to them. Others interfere
with the ability of tumor cells to grow and spread. Giving vinflunine together with cetuximab
may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving vinflunine together with cetuximab
works as second-line therapy in treating patients with stage IIIB or stage IV non-small cell
lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)